NEW YORK (GenomeWeb News) - Stratagene said today that it has acquired an exclusive licensing option to a family of patents related to bladder cancer owned by Denmark’s AROS Applied Biotechnology.
Under the agreement, Stratagene has the right to evaluate and exclusively license the rights to certain gene groups that have predictive capabilities for bladder cancer.
The agreement expands Stratagene’s molecular diagnostics intellectual property portfolio. The company said it will use the patents to develop Strategene-branded test kits and products.
Financial details were not disclosed.